Trials / Terminated
TerminatedNCT00497679
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1152 | 7-day continuous intravenous infusion |
Timeline
- Start date
- 2006-08-01
- Completion
- 2007-07-01
- First posted
- 2007-07-09
- Last updated
- 2009-05-14
Locations
3 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00497679. Inclusion in this directory is not an endorsement.